Next Article in Journal
Repurposing Plant Virus Nanoparticles
Previous Article in Journal
Radiation and Anti-Cancer Vaccines: A Winning Combination

Virus-Like-Vaccines against HIV

Department of Immunology and Microbiology (ISIM), Faculty of Health Sciences, University of Copenhagen, The Panum Institute Building 7-13-16, Blegdamsvej 3B, DK2200 Copenhagen, Denmark
Author to whom correspondence should be addressed.
Current address: Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.
Vaccines 2018, 6(1), 10;
Received: 4 January 2018 / Revised: 2 February 2018 / Accepted: 10 February 2018 / Published: 11 February 2018
Protection against chronic infections has necessitated the development of ever-more potent vaccination tools. HIV seems to be the most challenging foe, with a remarkable, poorly immunogenic and fragile surface glycoprotein and the ability to overpower the cell immune system. Virus-like-particle (VLP) vaccines have emerged as potent inducers of antibody and helper T cell responses, while replication-deficient viral vectors have yielded potent cytotoxic T cell responses. Here, we review the emerging concept of merging these two technologies into virus-like-vaccines (VLVs) for the targeting of HIV. Such vaccines are immunologically perceived as viruses, as they infect cells and produce VLPs in situ, but they only resemble viruses, as the replication defective vectors and VLPs cannot propagate an infection. The inherent safety of such a platform, despite robust particle production, is a distinct advantage over live-attenuated vaccines that must balance safety and immunogenicity. Previous studies have delivered VLVs encoded in modified Vaccinia Ankara vectors and we have developed the concept into a single-reading adenovirus-based technology capable of eliciting robust CD8+ and CD4+ T cells responses and trimer binding antibody responses. Such vaccines offer the potential to display the naturally produced immunogen directly and induce an integrated humoral and cellular immune response. View Full-Text
Keywords: virus vectors; virus-like-particles; T cells; antibodies; HIV; virus-like-vaccines virus vectors; virus-like-particles; T cells; antibodies; HIV; virus-like-vaccines
Show Figures

Figure 1

MDPI and ACS Style

Andersson, A.-M.C.; Schwerdtfeger, M.; Holst, P.J. Virus-Like-Vaccines against HIV. Vaccines 2018, 6, 10.

AMA Style

Andersson A-MC, Schwerdtfeger M, Holst PJ. Virus-Like-Vaccines against HIV. Vaccines. 2018; 6(1):10.

Chicago/Turabian Style

Andersson, Anne-Marie C., Melanie Schwerdtfeger, and Peter J. Holst 2018. "Virus-Like-Vaccines against HIV" Vaccines 6, no. 1: 10.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop